A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 281 sites in 17 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-03.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one has the largest enrollment, is one of 3 that started in 2013, is one of 20 in phase 3, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,681 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 6th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2013, is one of 121 in phase 3, and was the 178th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral and additional asthma controllers.
Exclusion criteria:
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Placebo administered subcutaneously
Biological: Placebo
Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Placebo subcutaneously on study week 0 until study week 44 inclusive.
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
Time frame: Immediately following the first administration of study drug through Study Week 48.
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
Time frame: Immediately following the first administration of study drug through Study Week 48.
Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations
The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)
Time frame: Immediately following the first administration of study drug through Study Week 48.
Number of Patients With >=1 Asthma Exacerbations
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time to First Asthma Exacerbation
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Change in Asthma Rescue Medication
Change from baseline to week 48 in number of rescue medication use (puffs/day)
Time frame: Immediately following the first administration of study drug through Study Week 48.
Home Lung Function Assessment Based on Morning PEF
Change from baseline to week 48 in home lung function morning peak expiratory flow \[PEF\]
Time frame: Immediately following the first administration of study drug through Study Week 48.
Home Lung Function Assessment Based on Evening PEF
Change from baseline to week 48 in home lung function evening peak expiratory flow \[PEF\]
Time frame: Immediately following the first administration of study drug through Study Week 48.
Proportion of Night Awakening Due to Asthma
Change from baseline to Week 48 on proportion of night awakening due to asthma
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Pharmacokinetics of Benralizumab
Mean PK concentrations at each visit
Time frame: Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56
Immunogenicity of Benralizumab
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Pre-treatment until end of follow-up
Extend of Exposure
Extend of exposure is defined as duration of treatment in days
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in AQLQ(S)+12
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Change From Baseline to Week 48 in EQ-5D-5L VAS
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Work Productivity Loss Due to Asthma
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Mean Productivity Loss Due to Asthma in Classroom
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes
Time frame: Immediately following the first administration of study drug through Study Week 48.
Number of Participants That Utilized Health Care Resources
Time frame: Immediately following the first administration of study drug through Study Week 48.
Patient and Clinician's Responder Assessment to Treatment
CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.
Time frame: Immediately following the first administration of study drug through Study Week 48
| Milestone | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Started | 400 | 398 | 407 |
| Received treatment | 399 | 398 | 407 |
| Completed | 354 | 358 | 367 |
| Not completed | 46 | 40 | 40 |
| Withdrew: Adverse event | 6 | 5 | 1 |
| Withdrew: Death | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 5 | 6 | 3 |
| Withdrew: Withdrawal by subject | 20 | 15 | 17 |
| Withdrew: Study-specific withdrawal criteria | 0 | 1 | 1 |
| Withdrew: Other reasons | 9 | 9 | 14 |
| Withdrew: Severe non-compliance to protocol | 4 | 2 | 2 |
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
| events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL | 0.73 (0.60 to 0.89) | 0.65 (0.53 to 0.80) | 1.33 (1.12 to 1.58) |
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
| events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL | 0.85 (0.65 to 1.11) | 1.00 (0.78 to 1.28) | 1.21 (0.96 to 1.52) |
The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)
| events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations | 0.11 (0.07 to 0.16) | 0.06 (0.04 to 0.11) | 0.18 (0.13 to 0.25) |
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Number of Patients With >=1 Asthma Exacerbations | 100 ± 84.227 | 93 ± 72.002 | 135 ± 74.434 |
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Time to First Asthma Exacerbation | NA ± 84.227 | NA ± 72.002 | 300 ± 74.434 |
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL | 0.353 ± 0.503 | 0.398 ± 0.546 | 0.237 ± 0.508 |
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL | 0.115 ± 0.417 | 0.238 ± 0.483 | 0.140 ± 0.4 |
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL | -1.15 ± 1.31 | -1.34 ± 1.27 | -1.03 ± 1.07 |
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL | -0.98 ± 1.19 | -1.04 ± 1.24 | -0.78 ± 0.99 |
Change from baseline to week 48 in number of rescue medication use (puffs/day)
| Puffs/day | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change in Asthma Rescue Medication | -2.74 ± 4.29 | -2.78 ± 3.90 | -2.18 ± 4.38 |
Change from baseline to week 48 in home lung function morning peak expiratory flow \[PEF\]
| L/min | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Home Lung Function Assessment Based on Morning PEF | 45.857 ± 84.227 | 36.994 ± 72.002 | 22.059 ± 74.434 |
Change from baseline to week 48 in home lung function evening peak expiratory flow \[PEF\]
| L/min | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Home Lung Function Assessment Based on Evening PEF | 36.806 ± 86.271 | 33.460 ± 74.017 | 14.784 ± 68.799 |
Change from baseline to Week 48 on proportion of night awakening due to asthma
| Proportion of nights | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Proportion of Night Awakening Due to Asthma | -0.314 ± 0.366 | -0.380 ± 0.385 | -0.26 ± 0.344 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL | -1.33 ± 1.18 | -1.47 ± 1.05 | -1.12 ± 1.15 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL | -0.77 ± 1.07 | -1.14 ± 1.11 | -0.89 ± 1.01 |
Mean PK concentrations at each visit
| ng/mL | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Baseline (n=395, 386) | NA ± NA | NA ± NA | — |
| Week 4 (n=393, 375) | 632.84 ± 152.14 | 629.89 ± 169.22 | — |
| Week 4 day 6 (n=54, 63) | 1368.98 ± 633.33 | 1273.7 ± 688.20 | — |
| Week 8 (n=377, 366) | 916.25 ± 142.53 | 881.57 ± 156.12 | — |
| Week 16 (n=358, 350) | 1024.26 ± 174.08 | 250.84 ± 228.25 | — |
| Week 24 (n=349, 344) | 926.62 ± 231.75 | 184.08 ± 298.92 | — |
| Week 32 (n=260, 267) | 853.67 ± 248.6 | 152.73 ± 394.18 | — |
| Week 40 (n=328, 333) | 967.15 ± 218.32 | 157.22 ± 364.6 | — |
| Week 48 (n=333, 333) | 864.37 ± 283.87 | 162.51 ± 352.46 | — |
| Week 56 (n=63, 67) | 51.7 ± 833.91 | 6.66 ± 321.88 | — |
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Positive at any visit (n=402, 393, 407) | 47 | 58 | 21 |
| Base- and post baseline positive (n=393, 381, 396) | 2 | 3 | 10 |
| Only post baseline positive (n=396, 389, 402) | 39 | 49 | 10 |
| Persistently positive (n=396, 389, 402) | 23 | 39 | 16 |
| Transiently positive (n=396, 389, 402) | 18 | 13 | 4 |
| Only baseline positive (n=399, 385, 401) | 6 | 6 | 1 |
Extend of exposure is defined as duration of treatment in days
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Extend of Exposure | 285.86 ± 67.446 | 288.02 ± 66.683 | 289.38 ± 61.527 |
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in AQLQ(S)+12 | 1.44 ± 1.18 | 1.56 ± 1.17 | 1.25 ± 1.18 |
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 48 in EQ-5D-5L VAS | 13.5 ± 21.82 | 16.5 ± 23.66 | 12.5 ± 21.41 |
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.
| Percent of productivity loss | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Work Productivity Loss Due to Asthma | 23.31 ± 24.169 | 26.11 ± 23.06 | 35.36 ± 24.537 |
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes
| Percent of productivity loss | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Productivity Loss Due to Asthma in Classroom | 30.97 ± 25.311 | 27.17 ± 38.456 | 49.1 ± 25.801 |
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Hospitalizations | 14 | 12 | 20 |
| Emergency department visits | 20 | 10 | 26 |
| Unscheduled outpatient visits | 77 | 87 | 109 |
| Home visits | 2 | 1 | 3 |
| Telephone calls | 46 | 41 | 62 |
| Ambulance transports | 6 | 3 | 9 |
CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| CGIC improved | 80 | 76 | 88 |
| CGIC much improved | 59 | 58 | 58 |
| CGIC very much improved | 18 | 12 | 5 |
| CGIC total responder | 157 | 146 | 151 |
| PGIC improved | 84 | 80 | 91 |
| PGIC much improved | 55 | 58 | 65 |
| PGIC very much improved | 26 | 19 | 11 |
| PGIC total responder | 165 | 157 | 167 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30 mg q.4 Weeks | — | 51/403 (12.7%) | 214/403 (53.1%) |
| Benralizumab 30 mg q.8 Weeks | — | 54/394 (13.7%) | 199/394 (50.5%) |
| Placebo | — | 58/407 (14.3%) | 219/407 (53.8%) |
| Event | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 23/403 | 24/394 | 32/407 |
| PneumoniaInfections and infestations | 0/403 | 2/394 | 3/407 |
| HypertensionVascular disorders | 0/403 | 2/394 | 0/407 |
| Cholecystitis acuteHepatobiliary disorders | 2/403 | 0/394 | 1/407 |
| InfluenzaInfections and infestations | 2/403 | 0/394 | 1/407 |
| Nasal polypsRespiratory, thoracic and mediastinal disorders | 2/403 | 0/394 | 1/407 |
| Urinary tract infection bacterialInfections and infestations | 0/403 | 0/394 | 2/407 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/403 | 0/394 | 2/407 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/403 | 0/394 | 2/407 |
| HypercoagulationBlood and lymphatic system disorders | 0/403 | 1/394 | 0/407 |
| Event | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 48/403 | 27/394 | 60/407 |
| NasopharyngitisInfections and infestations | 47/403 | 47/394 | 49/407 |
| Upper respiratory tract infectionInfections and infestations | 45/403 | 32/394 | 37/407 |
| HeadacheNervous system disorders | 31/403 | 37/394 | 21/407 |
| BronchitisInfections and infestations | 27/403 | 19/394 | 30/407 |
| SinusitisInfections and infestations | 18/403 | 22/394 | 29/407 |
| PharyngitisInfections and infestations | 17/403 | 23/394 | 14/407 |
| InfluenzaInfections and infestations | 15/403 | 19/394 | 23/407 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/403 | 18/394 | 12/407 |
| PyrexiaGeneral disorders | 16/403 | 12/394 | 8/407 |
| Age, Continuous(Years) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Mean | 50.1 ± 13.4 | 47.6 ± 14.5 | 48.7 ± 14.9 | 48.8 ± 14.3 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Female | 275 | 252 | 269 | 796 |
| Male | 124 | 146 | 138 | 408 |
Showing the first 100 of 281 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2013, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab